The Power of Focus in Building Companies: Divi's Lab Case Study | Saurabh Mukerjea x Salil Desai

Divi's Laboratories could enter a market worth more than $800 billion tomorrow. It has the chemistry. It has the customers. It has refused for 35 years.Saurabh Mukherjea and his co-author Salil Desai, Marcellus' Head of Research, on why that refusal is the first trait in their new book, The Art of Enduring.Divi's makes active pharmaceutical ingredients — paracetamol is the API, Crocin is the tablet built around it — and supplies roughly 70% of the world's dextromethorphan. It will not make the tablet, because the companies that do are its customers, and it has said so in print since its 2007 annual report. From FY06 to FY25, revenue and profit after tax both grew at around 20% a year.Chapters00:00:00 Coming Up00:01:30 Three Traits of Enduring Companies00:02:19 Trait One: Knowing Your Core00:02:33 Why Focus Is So Hard00:04:22 Bruce Lee on the Same Kick00:04:59 Divi's Laboratories and the API Business00:06:18 70% of the World's Dextromethorphan00:06:30 Why Not Make the Tablet?00:08:20 The Cardinal Sin in Business00:12:06 Contrast Media and Nutraceuticals00:15:05 Why Focus Lifts Returns on Capital00:23:09 Investing with MarcellusInvest with Marcellus: https://invest.marcellus.in/auth?utm_source=Spotify&utm_medium=organic&utm_campaign=ArtOfEnduringCoreStrengths&utm_id=PodcastMarcellus Investment Managers is a SEBI, US SEC, and IFSCA registered portfolio manager. Discover our approach to investing here: www.marcellus.in